益生菌联合序贯疗法与标准四联疗法治疗幽门螺杆菌感染的疗效及不良反应比较

Comparative study on clinical efficacy and adverse reactions of probiotics combined with sequential therapy and quadruple therapy in the treatment of helicobacter pylori infection

目的比较益生菌联合序贯疗法与标准四联疗法治疗幽门螺杆菌感染的疗效及不良反应。方法选择2014年3月—2015年3月笔者所在医院收治的幽门螺杆菌相关性胃炎116例,分为两组,各58例。对照组给予标准四联疗法,观察组给予益生菌联合序贯疗法。对两组患者的临床疗效及不良反应发生率进行比较。结果1治疗后观察组患者的幽门螺杆菌根除率(91.38%)明显高于对照组(72.41%),具有显著性差异(P<0.05)。2治疗后观察组患者的不良反应发生率(12.07%)明显低于对照组(36.21%),具有显著性差异(P<0.05)。3治疗后观察组患者对药物耐受程度明显高于对照组,具有显著性差异(P<0.05)。结论益生菌联合序贯疗法治疗幽门螺杆菌相关性胃炎,可明显提高幽门螺杆菌根除率,减轻患者的不良反应,改善患者对药物耐受程度,值得临床推广与应用。

Objective To compare clinical efficacy and adverse reactions of probiotics combined with sequential therapy and quadruple therapy in the treatment of helicobacter pylori infection. Methods Totally 116 patients with helicobacter pylori associated gastritis in author＇s hospital from March 2014 to March 2015 were randomly divided into two groups,5$ cases in each group. The patients in control group were treated with quadruple therapy while the patients in observation group were received probiotics combined with sequential therapy. Clinical efficacy and the incidence of adverse reactions in two groups were compared. Results 1） The Hp eradication rate in observation group （91.38%） after treatment was significantly higher than that in control group（72.41%）. 2） The incidence of adverse reactions in observation group（12.07%） was significantly lower than that in control group （36.21%）（P〈0.05）. 3） The drug tolerance of patients in observation group was significantly higher than that in control group （P〈0.05）. Conclusion Probiotics combined with sequential therapy in the treatment of helicobacter pylori infection can enhance clinical efficacy,reduce adverse reactions and improve the drug tolerance. It is worthy of promotion and application.